UChicago Genetics in Clinical Cancer Care: From Family Reunions to the Frontline of Developmental Therapeutics


 

Targeted Therapy for High-Risk Myeloid Malignancies: Aza+/-Ven in Older AML Disease, Aza/Dec for MDS, Ven+Aza in Treatment-Naïve MDS, Ena/Ivo for IDH-Mutated MPN

91 views
February 15, 2021
Comments 0
Login to view comments. Click here to Login